chimeric-antigen-receptor-t-cell-manufacturing-on-an-automated-cell

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Chimeric antigen receptor (CAR)-T cells represent a promising immunotherapeutic approach for the treatment of various malignant and non-malignant ...

Children’s Hospital of Philadelphia

Sufficient doses of viable CD34+ (vCD34) hematopoietic progenitor cells (HPCs) are crucial for engraftment. Additional-day apheresis collections can compensate for potential loss during cryopreservation but incur high cost and additional risk. To aid predicting such losses for clinical decision support, we developed a machine-learning model using variables obtainable on the day of collection.

Nicholas Giacobbe

Cell and Gene Therapy Laboratory,
Department of Pathology and Laboratory Medicine,
Cell and Gene Therapy Laboratory, Department of Pathology and Laboratory Medicine

Children’s Hospital of Philadelphia

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Nicholas Giacobbe

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Cell and Gene Therapy Laboratory,Department of Pathology and Laboratory Medicine,Cell and Gene Therapy Laboratory, Department of Pathology and Laboratory Medicine

Children’s Hospital of Philadelphia

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Cell and Gene Therapy Laboratory,
Department of Pathology and Laboratory Medicine,
Cell and Gene Therapy Laboratory, Department of Pathology and Laboratory Medicine